Good morning, everyone, and welcome to another working week. And this should be an exciting one, yes? After all, there is an election taking place and who knows what may happen. All the more reason to start quaffing cups of stimulation to prepare for whatever lies ahead. On that note, we also offer you some tidbits. Hope you have a productive day and please keep us in mind when something intriguing occurs. We accept secret documents, you know …
The battle over Prop 61 — the California ballot measure aimed at lowering drug prices — looks to be tightening, Reuters reports. The measure would require state agencies to pay the same as the Department of Veterans Affairs. A survey of nearly 1,500 registered voters at the end of October found 47 percent of voters would vote yes and 47 percent would vote no. The pharmaceutical industry donated $109 million to fight the effort.
New data-driven pricing plans drug makers are trying to replace the “pay-per-pill” approach are increasingly used for cancer treatments but will take longer for other conditions, such as multiple sclerosis, Jens Grueger, who heads global pricing and market access at Roche, tells Reuters. “At this point in time, we don’t see a way that it would practically work. The data are not available, but it would be very much in line with our pricing philosophy.”
Johnson & Johnson wants to have lawsuits claiming its talcum powder caused women to develop ovarian cancer moved to a different court, Reuters reports. The health care giant is attempting this gambit after losing a $67.5 million jury verdict last month, which marked its third straight trial defeat. All three awards, totaling around $195 million, were handed down in state court in St. Louis, with the same judge presiding.
Two Pakistani nationals held in custody since their 2012 arrest have been sentenced to time served for operating websites from 2005 to 2012 that illegally shipped $2 million of pharmaceuticals from Pakistan and the United Kingdom to other countries, according to federal prosecutors.
The UK’s Medicines and Healthcare products Regulatory Agency has launched a social media campaign to raise awareness of side effects and improve the public’s understanding of how to report them, PMLive says.
Cancer Research UK is partnering with the Wellcome Trust, Syncona, and BACIT to create a new public company with assets up to $1.2 billion to invest in life sciences, PharmaTimes tells us.
Roche is pursuing two skin cancer trials that combine its Tecentriq immunotherapy and other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, Reuters says.
Merck KGaA employees in Pakistan protested at the German embassy in hopes of receiving severance payments they argue are due after the drug maker sold a majority stake in its operations in the country, Dawn reports.
India and the UK signed memoranda of understanding on intellectual property rights that envisions establishing a mechanism for promoting cooperation between intellectual property offices, the Economic Times says.